ClinicalTrials.gg
RecruitingNCT06979700WAKE-OHCAUpdated Nov 18, 2025

Early WAKE-up Predictors After Out-of-Hospital Cardiac Arrest

An observational study in Cardiac Arrest (CA), Anoxic Brain Injury and Comatose Survivors of Cardiac Arrest, sponsored by University of Aarhus. Recruiting at 2 sites in Denmark. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-11-18.

Sponsored by University of Aarhus · Observational

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
250
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 36 studies in Heart Arrest with a site in Denmark — 6 open to participants now, 11 under way, none of them phase 3. Heart Arrest · Denmark.

Planned enrollment
4th of 10
250 · median 157
Started
2025
with 2 others
Observational
10 of 36
2 open now
Primary completion
2027-09
later than 8 of 10 live
Registered
35th of 36
by date
Lead sponsor
8 of 36
University of Aarhus

Among the 36 studies in Heart Arrest with a site in Denmark, this one is the 4th largest by planned enrollment of the 10 observational ones that give a count, is one of 3 that started in 2025, is one of 10 observational ones, reaches primary completion later than 8 of the 10 other live ones, and was the 35th registered.

Heart Arrest

927 studies on the registry are indexed under Heart Arrest; 227 are open to participants now.

Browse Heart Arrest studies →

Open to participants now

6 of the 36 studies in Heart Arrest with a site in Denmark are open now. Recruiting first, the newest first:

All 6 open studies →

A study can be open while its sites in Denmark have not opened yet or have stopped. Only those recruiting at a site in Denmark →

Who these studies take

Of the 157 Heart Arrest studies recruiting now, 109 (69%) set no upper age limit and 28 (18%) stop at 75 or younger; 30 take children under 18; 18 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 36 studies in Heart Arrest with a site in Denmark, or all of them as a file.
02

Study summary

WAKE-OHCA is a prospective observational substudy of the Danish Out-of-Hospital Cardiac Arrest (DANOHCA) trial, identifier NCT05895838. The aim is to collect early neuromonitoring data to identify key predictors of successful wake-up.

Read the detailed description

Background:

Post-resuscitation care following out-of-hospital cardiac arrest remains a critical area of research to optimize neurological recovery and cardiovascular outcomes. Recent findings from the Targeted Temperature Management (TTM) trials have led to the discontinuation of therapeutic hypothermia in Denmark, eliminating the need for deep sedation. The optimal sedation strategy in post-resuscitation care remains unknown, with sedation hypothesized to be neuroprotective controlling intracranial pressure but also known to be harmful and associated with adverse outcomes such as delirium, ventilator associated pneumonia, venous thromboembolism, prolonged intensive care unit (ICU) stay, delayed mobilization and patient prognostication.

Though there is emerging interest in early weaning from sedation within post-resuscitation care, limited data exist on its feasibility, prognostic implications and cost-effectiveness. Certain neuromonitoring modalities including automated pupillometry, transcranial doppler and electroencephalography (EEG) have shown promising prognostic properties, also in predicting favorable outcomes. However, sparse literature exists on early (\<6 hours) prognostication related to length of sedation, and further knowledge in this area is needed to support clinical decision making.

The Danish Out-of-Hospital Cardiac Arrest (DANOHCA) study (NCT05895838) is an on-going multicenter randomized trial enrolling 1,000 participants to early wake-up (\<6 hours) or standard (28-36 hours) length of sedation. This provides an opportunity to further understand neuroprognostication related to length of sedation in post-resuscitation care.

Aim and hypothesis:

This present study is designed within the context of the DANOHCA trial with the aim of identifying patient and neuromonitoring predictors of successful early and late wake-up.

The hypothesis is: Specific patient variables and neuromonitoring parameters are associated with successful wake-up.

Materials and Methods:

WAKE-OHCA will be conducted as a two-part analysis with 1) entire DANOHCA cohort (n=1,000 participants) with ICU admission data and 2) neuromonitoring data collected within the ICU on the patient cohorts at two Danish university hospital sites (Aarhus University Hospital and Rigshospitalet) during the study inclusion period (anticipated n=250 participants, with the exception of n=100 participants for EEG measurements, as these will only be performed at Aarhus University Hospital site).

DANOHCA inclusion criteria are: Out-of-hospital cardiac arrest of a presumed cardiac cause, age > 18 years, sustained return of spontaneous circulation for more than 20 minutes, unconscious upon admission.

The first part will include baseline characteristics, cardiac arrest data, and initial biochemistry. Data is collected from Danish prehospital patient journal (PPJ), electronic patient journals (EPJ, Sundhedsplatformen), Danish cardiac arrest registry and DANOHCA patient database.

The second part will include the following non-invasive neuromonitoring data collected prospectively at 0-6 hours, 20-28 hours, 44-52 hours and 66-72 hours after enrolment:

  • Bilateral automated pupillometry
  • Transcranial doppler evaluating both middle cerebral arteries.
  • Bilateral Optic Nerve Sheath Diameter measured by ultrasound.
  • Continuous 4-channel EEG background activity and EEG reactivity tests.

These will provide insight on early neurological status and recovery patterns, cerebral hemodynamics and intracranial pressure. Neuromonitoring data will only be collected on participants that are still comatose. Clinicians will be blinded from collected data, and it will have no impact on participants' treatment.

Automated pupillometry will be done with a NeurOptics NPi-200 pupillometer (NeurOptics, Irvine, California, USA). Transcranial doppler and ONSD measurements will be conducted with a Vivid S70N (GE Healthcare, Chicago, IL, USA) and analysed using Echopac (GE Healthcare, Chicago, IL, USA). EEG measurements will be done with Mindray BeneVision N-series with an aEEG module (Shenzhen Mindray Bio-Medical Electronics Co., Nanshan, Shenzhen, China).

Logistic regression analysis will be conducted to explore the association between participant and neuromonitoring variables and successful wake-up with unsuccessful wake-up as reference group. Secondary analyses will investigate how neuromonitoring variables perform in predicting patient outcomes (mortality, neurological outcome) in the early and late wake-up groups as well as how serial neuromonitoring variables are associated with successful wake-up at later stages.

Significance:

By identifying key predictors of early wake-up success, this project may refine patient selection, optimize individualized treatment, and enhance prognostication. Insights into neuromonitoring could improve clinical decision-making and reduce unnecessary sedation, minimizing associated complications.

03

Conditions studied

  • Cardiac Arrest (CA)
  • Anoxic Brain Injury
  • Comatose Survivors of Cardiac Arrest
  • EEG
  • Pupillometry
  • Optic Nerve Sheath Diameter
  • Transcranial Doppler Ultrasound
  • Neurological Outcome

Keywords

  • wakeup
  • sedation
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Patients enrolled in the DANOHCA trial at Aarhus University Hospital and Rigshospitalet.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age ≥18 years
  • OHCA of presumed cardiac cause
  • Sustained ROSC, defined as persistent signs of circulation and no need for chest compressions or mechanical circulatory support for 20 minutes
  • Unconsciousness (GCS \<9) (patients not able to obey verbal commands) after sustained ROSC at the time of randomization

Exclusion criteria

Exclusion Criteria:

  • Females of if pregnancy is suspected (unless a negative HCG test can rule out pregnancy within the inclusion window)
  • Known bleeding diathesis (medically induced coagulopathy (e.g. warfarin, NOAC, clopidogrel) does not exclude the patient)
  • Suspected or confirmed acute intracranial bleeding
  • Suspected or confirmed acute stroke
  • Unwitnessed asystole
  • Known limitations in therapy and Do Not Resuscitate-order
  • Known disease making 180 days survival unlikely
  • Known pre-arrest CPC 3 or 4 functional status
  • >3 hours (180 minutes) from ROSC to screening
  • Systolic blood pressure \<80 mm Hg despite fluid loading/vasopressor and/or inotropic medication (If the systolic blood pressure is recovering during the inclusion window of 180 minutes the patient may be included)
  • Use of intra-aortic balloon pump/axial flow device/ECMO (If the patient is weaned and the device is removed during the inclusion window of 180 minutes the patient may be included)
  • Temperature on admission \<30°C
  • Known allergy for dexamethasone or olanzapine
  • Ongoing (within 48 h) treatment with olanzapine or dexamethasone
  • Known back or hip condition that precluded the patients from being positioned with backrest from 0 to 45-degree angle
  • Known or suspected Long Syndrome (LQTS)
  • Known active fungal disease. Localized skin lesions do not exclude patients from inclusion
  • Estimated body weight \<45kg
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
250 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testAutomated Pupillometry

    Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment for both pupils and include: Neurological pupil index, pupillary size, pupillary minimum diameter, pupillary constriction amplitude, pupillary constriction velocity, pupillary maximum constriction velocity, pupillary latency and pupillary dilation velocity.

  • Diagnostic testTranscranial Doppler Ultrasound

    Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment on both middle cerebral arteries and include the following: Peak systolic velocity, end diastolic velocity, mean velocity, pulsatility index and resistance index.

  • Diagnostic testOptic Nerve Sheath Diameter

    Measurements will be performed on comatose participants at 0-6 hours, 20-28, 44-52 and 66-72 hours after enrolment on both eyes using ultrasound and include the following: optic nerve sheath diameter of right and left side and mean optic nerve sheath diameter.

  • Diagnostic testContinuous EEG and EEG Reactivity

    Continuous 4-channel EEG will be established on participants as soon as possible within 0-6 hours. EEG will be stopped at successful extubation or when 72 hours has passed since study inclusion. EEG Reactivity will be performed on comatose participants at the following times: 0-6, 20-28, 44-52 and 66-72 hours after study inclusion. Reactivity includes 7 standardized stimuli, including 1 visual, 3 auditive and 3 pain stimuli. EEG data will be reviewed in Stratus EEG Analysis (Kvikna Mediacal ehf. version 5.1). Timestamps for EEG-reactivity will be manually inserted in the file. EEG Reactivity will be analysed quantitatively by power spectrum analyses performed in LabVIEW 2016 (National Instruments) according to the principles of a previous method (PMID: 36041343). Background activity within 5 minutes following reactivity stimuli, prioritizing time periods without artifacts, will be analysed by power spectrum analyses, Mindray quantitative analysis and manually analyzed by experts.

06

What researchers measure

Primary outcomes

  1. Number of patients with successful wake-up

    Defined as awake and successfully extubated.

    Time frame: 0-6 hours or 28-36 hours according to DANOHCA randomization.

Secondary outcomes

  1. Number of patients with successful delayed wake-up

    Defined as awake and successfully extubated later than according to DANOHCA randomization.

    Time frame: Up to 90 days.

  2. Duration of intubation

    Assessed as the duration of intubation from randomization till extubation during initial ICU stay (oral and tracheostomy combined).

    Time frame: Up to 90 days.

  3. Days alive outside hospital

    Counted as days alive outside of hospital after discharge.

    Time frame: 30 days.

  4. 30-day mortality

    Number of patients dying from all causes.

    Time frame: 30 days.

  5. 90-day mortality

    Number of patients dying from all causes.

    Time frame: 90 days.

  6. Length of ICU stay

    Assessed as the initial ICU length of stay.

    Time frame: From randomization till discharge from the ICU, up to 90 days.

  7. Length of hospital stay

    Assessed as the hospital length of stay (including in-patient rehabilitation and transfer to referral hospital).

    Time frame: From randomization till discharge from hospital or in-patient rehabilitation, up to 90 days.

  8. Cerebral Performance Category (CPC)

    CPC score at ICU discharge, at hospital discharge, and at ambulatory follow-up (scheduled visit at 3 to 6 months after the cardiac arrest). The CPC score ranges from 1 to 5 with higher scores indicating worse outcomes.

    Time frame: Up to 6 months.

07

Study locations

2 of 2 sites recruiting
  • Department of Intensive Care Medicine
    Aarhus N, DK-8200, Denmark
    Recruiting
    • Christopher Torp Lohse, MD · Contactchtorp@rm.dk · +4526745886
    • Anders Grejs, MD, PhD · Contactandgre@rm.dk · +4551948171
    • Christopher Torp Lohse, MD · Principal investigator
  • Department of Cardiology, The Heart Centre, Rigshospitalet
    Copenhagen, DK-2100, Denmark
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Sep 2027, 28 months after the start.

Of 169 non-industry observational studies under Heart Arrest, half reached primary completion within 41 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 96. This study's planned 28 months is below that.

Counting every sponsor, half of 176 studies reached it within 41 months; a quarter within 18 and three quarters within 90.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2025
First posted
May 20, 2025
StartActual
May 13, 2025
Primary completionEst.
Sep 2027
CompletionEst.
Dec 2027
Last update
Nov 18, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 18, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06979700
Responsible party
Sponsor
First posted
May 20, 2025
Start date
May 13, 2025
Primary completion
Sep 2027 (estimated)
Completion
Dec 2027 (estimated)
Last update
Nov 18, 2025

Study contacts

Christopher Torp Lohse, MD
Contact
chtorp@rm.dk
+4526745886
Anders Grejs, MD, PhD
Contact
andgre@rm.dk
+4551948171
Christian Hassager, MD, DMSc
study chair · Department of Cardiology, Rigshospitalet

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion